Breast Cancer

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.

T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive breast cancer/triple-negative breast cancer in DESTINY-Breast04.

Data from the ELEVATE trial may support elacestrant as an endocrine therapy backbone in ER-positive, HER2-negative metastatic breast cancer.

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

The use of chemotherapy trended toward improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

In the phase 3 DESTINY-Breast06 trial, the overall biomarker-evaluable population’s confirmed ORR was 59.4% with T-DXd vs 33.9% with chemotherapy.

Across all 3 treatment arms, global health status/quality of life and functional domains were maintained in the phase 3 EMBER-3 trial.

Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.